According to The Insight Partners' research, the Asia Pacific DNA Plasmid Manufacturing Market was valued at US$ 171.2 Million in 2024 and is expected to reach US$ 676.6 Million by 2031, registering a CAGR of 21.9% from 2025 to 2031.
Expansion of contract development and manufacturing organizations (CDMOs) and growing research on DNA plasmid vaccine development are among the critical factors attributed to the Asia Pacific DNA plasmid manufacturing market expansion.
The growing complexity of gene therapies and increasing regulatory demands have led to a significant rise in outsourcing plasmid DNA production to specialized Contract Development and Manufacturing Organizations (CDMOs). These CDMOs offer scalable, GMP-compliant manufacturing capabilities, enabling biopharmaceutical companies to accelerate time-to-market and avoid the high capital costs of building in-house facilities. Two leading CDMOs in this field are Aldevron, a Danaher company known for its high-quality plasmid DNA used in gene and cell therapies and mRNA vaccines, and VGXI, a subsidiary of GeneOne Life Science, recognized for its proprietary Helixfermentation technology and end-to-end-plasmid-DNA-service. Both have made significant investments to expand production capacity and meet the growing global demand for plasmid-based therapeutics.
In April 2025, ProBio-a global CDMO-announced the launch of its GMP plasmid DNA manufacturing service at its Hopewell facility. This new service enables the production of clinical-grade plasmid DNA from cell bank to batch release in three months, significantly faster than standard industry timelines. The offering provides reliable and accelerated access to high-quality plasmid DNA aimed at supporting gene and cell therapy developers. ProBio ensures that every batch-ranging from small-scale (50-200 mg) to gram-level quantities-meets client specifications with complete transparency and no hidden fees.
In June 2024, Bionova Scientific, a full-service biologics CDMO and part of the Asahi Kasei Group, announced a US$100 million investment to expand into plasmid DNA (pDNA) manufacturing. This investment aims to build a 100,000-square-foot development and production facility in The Woodlands, Texas, near Houston. Set to become operational in the first quarter of 2025, the facility will initially offer pDNA development services along with the production of research-grade and high-quality pDNA, with GMP manufacturing capabilities expected to come online in early 2026. Therefore, the expansion of CDMOs is expected to offer lucrative opportunities to the DNA plasmid manufacturing market in the coming years.
On the contrary, high manufacturing costs hamper the growth of the Asia Pacific DNA plasmid manufacturing market.
Asia Pacific DNA Plasmid Manufacturing Market Segmentation Analysis:
- By Product Type, the Asia Pacific DNA Plasmid Manufacturing Market is segmented into GMP Grade and R&D Grade. The GMP Grade segment is projected to expand at 22.1% CAGR during 2025 - 2031.
- By Application, the Asia Pacific DNA Plasmid Manufacturing Market is segmented into Cell and Gene Therapy, DNA Vaccines, Immunotherapy, and Others. The Cell and Gene Therapy segment is projected to expand at 22.4% CAGR during 2025 - 2031.
- By End User, the Asia Pacific DNA Plasmid Manufacturing Market is segmented into Pharmaceutical and Biotechnology Companies, CROs and CDMOs, and Others. The Pharmaceutical and Biotechnology Companies segment is projected to expand at 21.5% CAGR during 2025 - 2031.
By country, the Asia Pacific DNA Plasmid Manufacturing Market is categorized into China, Japan, India, Australia, South Korea, and the Rest of APAC. China is projected to expand at 22.2% CAGR during 2025 - 2031.
Key players operating in the DNA Plasmid Manufacturing Market are Charles River Laboratories International Inc, Catalent Inc, WuXi Biologics Inc, Sartorius AG, GenScript Biotech Corporation, Takara Bio Inc, AGC Biologics AS, Thermo Fisher Scientific Inc., SK Pharmteco Inc., and Creative Biogene, among others.
- In February 2025, WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it has again passed the GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities (MFG2 and MFG5) in Wuxi city.
- In July 2024, Charles River Laboratories International, Inc. and AAVantgarde announced a contract development and manufacturing organization (CDMO) agreement to produce Good Manufacturing Practice- (GMP) plasmid DNA. AAVantgarde, a clinical-stage biotechnology company with two proprietary adeno-associated viral (AAV) vector platforms for large gene delivery and developing products to treat inherited retinal diseases, will leverage Charles River's expertise in manufacturing GMP plasmid DNA.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com